Engineered cardiac tissues: a novel in vitro model to investigate the pathophysiology of mouse diabetic cardiomyopathy.

Abstract

Rodent diabetic models, used to understand the pathophysiology of diabetic cardiomyopathy (DCM), remain several limitations. Engineered cardiac tissues (ECTs) have emerged as robust 3D in vitro models to investigate structure-function relationships as well as cardiac injury and repair. Advanced glycation end-products (AGEs), produced through glycation of proteins or lipids in response to hyperglycemia, are important pathogenic factor for the development of DCM. In the current study, we developed a murine-based ECT model to investigate cardiac injury produced by AGEs. We treated ECTs composed of neonatal murine cardiac cells with AGEs and observed AGE-related functional, cellular, and molecular alterations: (1) AGEs (150 µg/mL) did not cause acute cytotoxicity, which displayed as necrosis detected by medium LDH release or apoptosis detected by cleaved caspase 3 and TUNEL staining, but negatively impacted ECT function on treatment day 9; (2) AGEs treatment significantly increased the markers of fibrosis (TGF-β, α-SMA, Ctgf, Collagen I-α1, Collagen III-α1, and Fn1) and hypertrophy (Nppa and Myh7); (3) AGEs treatment significantly increased ECT oxidative stress markers (3-NT, 4-HNE, HO-1, CAT, and SOD2) and inflammation response markers (PAI-1, TNF-α, NF-κB, and ICAM-1); and (4) AGE-induced pathogenic responses were all attenuated by pre-application of AGE receptor antagonist FPS-ZM1 (20 µM) or the antioxidant glutathione precursor N-acetylcysteine (5 mM). Therefore, AGEs-treated murine ECTs recapitulate the key features of DCM's functional, cellular and molecular pathogenesis, and may serve as a robust in vitro model to investigate cellular structure-function relationships, signaling pathways relevant to DCM and pharmaceutical intervention strategies.

• Authors: Xiang Wang, Xin-Xin Chen, Hai-Tao Yu, Yi Tan, Qian Lin, Bradley B Keller, Yang Zheng, Lu Cai
• Journal: Acta pharmacologica Sinica (Acta Pharmacol Sin) Vol. 42 Issue 6 Pg. 932-941 (Jun 2021) ISSN: 1745-7254 [Electronic] United States
• PMID: 33037406 (Publication Type: Journal Article)

Chemical References

• Benzamides
• FPS-ZM1
• Glycation End Products, Advanced
• Receptor for Advanced Glycation End Products
• Acetylcysteine

Topics

• Acetylcysteine (pharmacology)
• Animals
• Benzamides (pharmacology)
• Cells, Cultured
• Diabetic Cardiomyopathies (chemically induced, complications, physiopathology)
• Glycation End Products, Advanced (pharmacology)
• Inflammation (chemically induced, complications, physiopathology)
• Mice
• Myocardium (metabolism)
• Myocytes, Cardiac (drug effects, metabolism)
• Oxidative Stress (drug effects)
• Receptor for Advanced Glycation End Products (antagonists & inhibitors, metabolism)
• Tissue Engineering